JPH07504813A - 新規蛋白質チロシンキナーゼ類 - Google Patents
新規蛋白質チロシンキナーゼ類Info
- Publication number
- JPH07504813A JPH07504813A JP5513345A JP51334593A JPH07504813A JP H07504813 A JPH07504813 A JP H07504813A JP 5513345 A JP5513345 A JP 5513345A JP 51334593 A JP51334593 A JP 51334593A JP H07504813 A JPH07504813 A JP H07504813A
- Authority
- JP
- Japan
- Prior art keywords
- identification number
- sequence identification
- sequence
- protein
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title claims description 66
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title claims description 50
- 108090000623 proteins and genes Proteins 0.000 claims description 52
- 102000004169 proteins and genes Human genes 0.000 claims description 37
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 34
- 108020004414 DNA Proteins 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 12
- 230000003197 catalytic effect Effects 0.000 claims description 10
- 210000003593 megakaryocyte Anatomy 0.000 claims description 9
- 108091008794 FGF receptors Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 108091008604 NGF receptors Proteins 0.000 claims description 6
- 108091071773 flk family Proteins 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 210000004885 white matter Anatomy 0.000 claims description 3
- 102000001253 Protein Kinase Human genes 0.000 claims description 2
- 108060006633 protein kinase Proteins 0.000 claims description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 3
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 3
- 239000000463 material Substances 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 101150020896 ptk gene Proteins 0.000 description 14
- 101100192359 Acinetobacter johnsonii ptk gene Proteins 0.000 description 11
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical group 0.000 description 10
- 239000003446 ligand Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 239000013615 primer Substances 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 102000009465 Growth Factor Receptors Human genes 0.000 description 4
- 108010009202 Growth Factor Receptors Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000004544 DNA amplification Effects 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011005 laboratory method Methods 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 101100290380 Caenorhabditis elegans cel-1 gene Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 241000975394 Evechinus chloroticus Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 241001245789 Goodea atripinnis Species 0.000 description 1
- 101150042441 K gene Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- VXOKDLACQICQFA-UHFFFAOYSA-N N-Desethylamiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCNCC)C(I)=C1 VXOKDLACQICQFA-UHFFFAOYSA-N 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101100170066 Rattus norvegicus Ddr1 gene Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003924 normoblast Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82693592A | 1992-01-22 | 1992-01-22 | |
| US826,935 | 1992-01-22 | ||
| PCT/US1993/000586 WO1993015201A1 (fr) | 1992-01-22 | 1993-01-22 | Nouvelles tyrosine kinases de proteines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH07504813A true JPH07504813A (ja) | 1995-06-01 |
Family
ID=25247892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5513345A Pending JPH07504813A (ja) | 1992-01-22 | 1993-01-22 | 新規蛋白質チロシンキナーゼ類 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0624192A1 (fr) |
| JP (1) | JPH07504813A (fr) |
| AU (1) | AU3482493A (fr) |
| CA (1) | CA2128722A1 (fr) |
| WO (1) | WO1993015201A1 (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728536A (en) * | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| US6331302B1 (en) | 1992-01-22 | 2001-12-18 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US5635177A (en) * | 1992-01-22 | 1997-06-03 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
| US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
| US6107046A (en) * | 1992-10-09 | 2000-08-22 | Orion Corporation | Antibodies to Flt4, a receptor tyrosine kinase and uses thereof |
| US5834208A (en) * | 1993-08-25 | 1998-11-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Tyrosine kinase |
| US5834441A (en) * | 1993-09-13 | 1998-11-10 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Adeno-associated viral (AAV) liposomes and methods related thereto |
| US6652850B1 (en) | 1993-09-13 | 2003-11-25 | Aventis Pharmaceuticals Inc. | Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity |
| US6287784B1 (en) | 1993-11-23 | 2001-09-11 | Genentech, Inc. | Kinase receptor activation assay |
| WO1995014776A1 (fr) | 1993-11-23 | 1995-06-01 | Genentech, Inc. | TYROSINE KINASES PROTEIQUES APPELEES Rse |
| US6001621A (en) * | 1993-11-23 | 1999-12-14 | Genetech, Inc. | Protein tyrosine kinases |
| CA2175892C (fr) * | 1993-11-23 | 2000-03-07 | Paul J. Godowski | Methode d'activation du recepteur de kinase |
| WO1995015386A1 (fr) * | 1993-12-02 | 1995-06-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Nouvelle tyrosine-kinase receptrice |
| US6506578B1 (en) * | 1994-04-22 | 2003-01-14 | Sugen, Inc. | Nucelotide encoding megakaryocytic protein tyrosine kinases |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| GB9410534D0 (en) * | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
| US5864020A (en) * | 1994-07-20 | 1999-01-26 | Genentech, Inc. | HTK ligand |
| WO1996026958A2 (fr) * | 1995-02-27 | 1996-09-06 | President And Fellows Of Harvard College | L'elf-2, ligand du recepteur eph |
| US6531296B1 (en) * | 1995-06-20 | 2003-03-11 | The University Of North Carolina At Chapel Hill | Nuclear tyrosine kinase Rak |
| ES2202469T5 (es) | 1995-09-08 | 2011-06-06 | Genentech, Inc. | Proteína relacionada con el vegf. |
| US5981201A (en) | 1997-01-08 | 1999-11-09 | Beth Israel Deaconess Medical Center | Methods of detection and treatment of breast cancer |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| US6887674B1 (en) | 1998-04-13 | 2005-05-03 | California Institute Of Technology | Artery- and vein-specific proteins and uses therefor |
| US6811992B1 (en) | 1998-05-14 | 2004-11-02 | Ya Fang Liu | Method for identifying MLK inhibitors for the treatment of neurological conditions |
| DK1119371T3 (da) | 1998-10-09 | 2011-03-07 | Vegenics Ltd | Flt4 (VEGFR-3) som et mål for tumorbilleddannelse og antitumorterapi |
| JP4669984B2 (ja) | 2001-01-19 | 2011-04-13 | ベジェニクス リミテッド | 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法 |
| JP4762889B2 (ja) | 2003-03-12 | 2011-08-31 | バスジーン セラピューティクス，インコーポレイテッド | 血管形成及び腫瘍成長を阻止するための核酸化合物 |
| US7381410B2 (en) | 2003-03-12 | 2008-06-03 | Vasgene Therapeutics, Inc. | Polypeptide compounds for inhibiting angiogenesis and tumor growth |
| CA2544074A1 (fr) | 2003-10-24 | 2005-05-06 | Esbatech Ag | Procede pour l'identification et/ou la validation d'inhibiteurs de tyrosine-kinases receptrices |
| CN101072797B (zh) | 2004-03-12 | 2012-05-09 | 瓦斯基因治疗公司 | 结合ephb4、抑制血管发生和肿瘤生长的抗体 |
| ATE492564T1 (de) | 2004-03-12 | 2011-01-15 | Vasgene Therapeutics Inc | Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum |
| EP1799713B1 (fr) | 2004-09-23 | 2014-11-05 | VasGene Therapeutics, Inc. | Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale |
| JP5749009B2 (ja) | 2007-08-13 | 2015-07-15 | バスジーン セラピューティクス，インコーポレイテッドＶａｓｇｅｎｅｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ＥｐｈＢ４に結合するヒト化抗体を利用する癌治療剤 |
| NZ717373A (en) | 2010-06-03 | 2017-11-24 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| RS60026B1 (sr) | 2013-02-18 | 2020-04-30 | Vegenics Pty Ltd | Molekuli koji vezuju ligande i njihove upotrebe |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0536350B1 (fr) * | 1991-02-22 | 2002-08-07 | American Cyanamid Company | Identification d'un nouveau gene humain recepteur de tyrosine kinase |
-
1993
- 1993-01-22 EP EP93903639A patent/EP0624192A1/fr not_active Withdrawn
- 1993-01-22 WO PCT/US1993/000586 patent/WO1993015201A1/fr not_active Application Discontinuation
- 1993-01-22 CA CA 2128722 patent/CA2128722A1/fr not_active Abandoned
- 1993-01-22 AU AU34824/93A patent/AU3482493A/en not_active Abandoned
- 1993-01-22 JP JP5513345A patent/JPH07504813A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0624192A1 (fr) | 1994-11-17 |
| AU3482493A (en) | 1993-09-01 |
| WO1993015201A1 (fr) | 1993-08-05 |
| CA2128722A1 (fr) | 1993-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH07504813A (ja) | 新規蛋白質チロシンキナーゼ類 | |
| JP3193301B2 (ja) | 生理活性タンパク質ｐ１６０ | |
| Holtrich et al. | Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. | |
| Bennett et al. | Cloning and characterization of HTK, a novel transmembrane tyrosine kinase of the EPH subfamily. | |
| Roussel et al. | A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes. | |
| US5457048A (en) | Eph-related tyrosine kinases, nucleotide sequences and methods of use | |
| Cai et al. | AND-34, a novel p130Cas-binding thymic stromal cell protein regulated by adhesion and inflammatory cytokines | |
| WO1996026958A2 (fr) | L'elf-2, ligand du recepteur eph | |
| Meyer et al. | Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands | |
| Muslin et al. | Phosphatidylinositol 3-kinase activity is important for progesterone-induced Xenopus oocyte maturation | |
| Miller et al. | Lemon encodes an unusual receptor protein-tyrosine kinase expressed during gametogenesis in Hydra | |
| Shalaby et al. | The regulatory subunit of a cGMP‐regulated protein kinase A of Trypanosoma brucei | |
| US6368796B1 (en) | Methods of detection and treatment of breast cancer | |
| US5753446A (en) | Mitogen ERK kinase kinase (MEKK) assay | |
| US7795416B2 (en) | Telomerase expression repressor proteins and methods of using the same | |
| JP2005519584A5 (fr) | ||
| US20050100999A1 (en) | Nucleic acid encoding receptor type protein kinase | |
| Nicola et al. | Molecular cloning of two novel transmembrane ligands for Eph-related kinases (LERKS) that are related to LERK-2 | |
| JP2004533206A (ja) | 化学療法のための標的としてのガン関連遺伝子 | |
| JP2002511735A (ja) | アダプター蛋白質ｆｒｓ２および関連する物質および方法 | |
| JP2004503211A (ja) | ヒトｎｉｍ１キナーゼ | |
| US20020164647A1 (en) | Protein-protein interactions | |
| Hughes et al. | Cloning and Chromosomal Localization of a Mouse cDNA with Homology to theSaccharomyces cerevisiaeGene Zuotin | |
| WO1996011212A1 (fr) | Nouveau ligand de tyrosine kinase de type recepteur | |
| Chu et al. | Identification and characterization of DBK, a novel putative serine/threonine protein kinase from human endothelial cells |